New insulin therapy demonstrates cardiovascular safety and reduces the risk of severe hypoglycemia

Results of the DEVOTE trial investigating the cardiovascular (CV) safety profile of long-acting insulin, insulin degludec (Tresiba), in adults with type 2 diabetes were presented at the American Diabetes Association (ADA) congress.  It also demonstrated a significantly lower rate of severe hypoglycaemia with insulin degludec treatment compared with insulin glargine U100. These findings, which are the first to specifically examine the CV impact of insulin degludec, provide further evidence to support its safety profile and are in line with previous studies. Dr Ponnusamy Saravanan, Associate Clinical Professor and Honorary Consultant Physician in Diabetes, Endocrinology & Metabolism, University of Warwick, commented: €œThere are four million people